The recent advances in our understanding of the DNA replication initiation machinery and its clinical translational exploitation in terms of anti-cancer therapy raise the important question as to whether targeting Cdc7 might be of clinical benefit in pancreatic cancer for which therapeutic options are limited. Here, CDC7 is linked to familial pancreatic carcinoma.